I moved RG 3477 (aka ACT-128800) from phase 1 to phase 2 based on this press release.

I removed “Atacicept (aka TACI-Ig) (Merck Serono and ZymoGenetics)” from the phase 2 list based on this article.

RTL1000 successfully completed a phase 1 trial, so I’m moving it to phase 2, based on this press release.

I moved PI-2301 from phase 1 to phase 2 based on this press release.

I moved Daclizumab from phase 2 to phase 3 based on this press release. The drug is still in a phase 2b trial for MS, but they are going ahead with planning for the phase 3 without waiting for the conclusion of the phase 2. I don’t know if this is because Facet Biotech is really confident in daclizumab, or if they are trying to impress investors or get some kind of milestone payment from Biogen.

I removed MBP8298 (aka Dirucotide) (BioMS) (trials for SPMS and RRMS) from both the phase 2 and phase 3 lists based on this press release.

I know a significant number of phase 3 candidates fail, but it’s still disappointing when one does, especially one that was being tested on progressive MS.

I removed CDP323 (UCB / Biogen) from the phase 2 list based on this news.

I added LY2127399 (Anti-BAFF Human Antibody) (Eli Lilly) to the phase 2 list based on this webpage.

Based on this information from a trial participant, I have removed “Lamotrigine (aka Lamictal) (SPMS) (Glaxosmithkline)” from the phase 2  list.

I added BAF312 (Novartis) to the phase 2 list based on this.